Behçet syndrome: a contemporary viewHasan Yazıcı, Yusuf Yazıcı, Emire Seyahi et al.|Nature Reviews Rheumatology|2018Cited by 438
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled StudyGülen Hatemi, Yusuf Yazıcı, Recep Tunç et al.|New England Journal of Medicine|2015Cited by 241
Behçet syndromeYusuf Yazıcı, Hasan Yazıcı, Gülen Hatemi et al.|Nature Reviews Disease Primers|2021Cited by 175
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's diseaseBenoît Melchior, Yusuf Yazıcı|Aging Cell|2019Cited by 64